155 related articles for article (PubMed ID: 23620766)
21. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation enables accurate assessment of HER2 genomic status in ovarian tumours.
Yan B; Choo SN; Mulyadi P; Srivastava S; Ong CW; Yong KJ; Putti T; Salto-Tellez M; Lim GS
J Clin Pathol; 2011 Dec; 64(12):1097-101. PubMed ID: 21896578
[TBL] [Abstract][Full Text] [Related]
22. Assessment of HER2 Status Using Immunohistochemistry (IHC) and Fluorescence In Situ Hybridization (FISH) Techniques in Mucinous Epithelial Ovarian Cancer: A Comprehensive Comparison between ToGA Biopsy Method and ToGA Surgical Specimen Method.
Chao WR; Lee MY; Ruan A; Sheng HP; Hsu JD; Han CP; Koo CL
PLoS One; 2015; 10(11):e0142135. PubMed ID: 26566289
[TBL] [Abstract][Full Text] [Related]
23. The prognostic value of HER2 status and efficacy of anti-HER2 therapy in patients with HR-positive mucinous breast cancer: a nationwide study from the Korean Breast Cancer Society.
Kim HS; Yoo TK; Park WC; Chae BJ
Breast Cancer Res Treat; 2020 Apr; 180(2):461-470. PubMed ID: 32020434
[TBL] [Abstract][Full Text] [Related]
24. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
[TBL] [Abstract][Full Text] [Related]
25. Long term survival outcomes of stage I mucinous ovarian cancer - A clinical calculator predictive of chemotherapy benefit.
Richardson MT; Mysona DP; Klein DA; Mann A; Liao CI; Diver EJ; Darcy KM; Tian C; She JX; Ghamande S; Van Le L; Kapp DS; Chan JK
Gynecol Oncol; 2020 Oct; 159(1):118-128. PubMed ID: 32828578
[TBL] [Abstract][Full Text] [Related]
26. [Association of HER2 protein expression with clinicopathologic features and prognosis in Chinese patients with gastric carcinoma].
Wu HM; Liu YH; Lin F; Xu FP; Luo DL; Zhang F; Zhuang HG; Luo XL; Wu WL; Lin XT
Zhonghua Bing Li Xue Za Zhi; 2011 May; 40(5):296-9. PubMed ID: 21756821
[TBL] [Abstract][Full Text] [Related]
27. MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features.
Lee H; Park CS; Deftereos G; Morihara J; Stern JE; Hawes SE; Swisher E; Kiviat NB; Feng Q
World J Surg Oncol; 2012 Aug; 10():174. PubMed ID: 22925189
[TBL] [Abstract][Full Text] [Related]
28. Human epidermal growth factor receptor 2 overexpression and amplification in mucinous tumours of ovary.
Gilks CB; McAlpine J
Histopathology; 2011 Jun; 58(7):1173-4. PubMed ID: 21707717
[No Abstract] [Full Text] [Related]
29. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.
Bagnoli M; Canevari S; Califano D; Losito S; Maio MD; Raspagliesi F; Carcangiu ML; Toffoli G; Cecchin E; Sorio R; Canzonieri V; Russo D; Scognamiglio G; Chiappetta G; Baldassarre G; Lorusso D; Scambia G; Zannoni GF; Savarese A; Carosi M; Scollo P; Breda E; Murgia V; Perrone F; Pignata S; De Cecco L; Mezzanzanica D;
Lancet Oncol; 2016 Aug; 17(8):1137-1146. PubMed ID: 27402147
[TBL] [Abstract][Full Text] [Related]
30. Expression of HER2/neu, estrogen and progesterone receptors, CA 125 and CA19-9 on cancer cell membrane in patients with serous and mucinous carcinoma of the ovary.
Karaferic A; Jovanovic D; Jelic S
J BUON; 2009; 14(4):635-9. PubMed ID: 20148455
[TBL] [Abstract][Full Text] [Related]
31. Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study.
Pignata S; Ferrandina G; Scarfone G; Scollo P; Odicino F; Cormio G; Katsaros D; Villa A; Mereu L; Ghezzi F; Manzione L; Lauria R; Breda E; Alletti DG; Ballardini M; Lombardi AV; Sorio R; Mangili G; Priolo D; Magni G; Morabito A
BMC Cancer; 2008 Sep; 8():252. PubMed ID: 18761742
[TBL] [Abstract][Full Text] [Related]
32. Relationship between HER2 and JAK/STAT-SOCS3 signaling pathway and clinicopathological features and prognosis of ovarian cancer.
Shang AQ; Wu J; Bi F; Zhang YJ; Xu LR; Li LL; Chen FF; Wang WW; Zhu JJ; Liu YY
Cancer Biol Ther; 2017 May; 18(5):314-322. PubMed ID: 28448787
[TBL] [Abstract][Full Text] [Related]
33. Molecular characterization of 103 ovarian serous and mucinous tumors.
Vereczkey I; Serester O; Dobos J; Gallai M; Szakács O; Szentirmay Z; Tóth E
Pathol Oncol Res; 2011 Sep; 17(3):551-9. PubMed ID: 21136228
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathological correlates and prognostic significance of KRAS mutation status in a pooled prospective cohort of epithelial ovarian cancer.
Nodin B; Zendehrokh N; Sundström M; Jirström K
Diagn Pathol; 2013 Jun; 8():106. PubMed ID: 23800114
[TBL] [Abstract][Full Text] [Related]
35. Implications of HER2 amplification in small, node-negative breast cancers: do Asians differ?
Wong FY; Yip CS; Chua ET
World J Surg; 2012 Feb; 36(2):287-94. PubMed ID: 22105650
[TBL] [Abstract][Full Text] [Related]
36. Analysis of the contribution of immunologically-detectable HER2, steroid receptors and of the "triple-negative" tumor status to disease-free and overall survival of women with epithelial ovarian cancer.
de Toledo MC; Sarian LO; Sallum LF; Andrade LL; Vassallo J; de Paiva Silva GR; Pinto GA; Soares FA; Fonseca CD; Derchain SF
Acta Histochem; 2014 Apr; 116(3):440-7. PubMed ID: 24238473
[TBL] [Abstract][Full Text] [Related]
37. HER2-positive pure mucinous breast carcinoma: A case report and literature review.
Zhao X; Yang X; Gao R; Zhai L; Yang L; Yu K
Medicine (Baltimore); 2020 Aug; 99(33):e20996. PubMed ID: 32871976
[TBL] [Abstract][Full Text] [Related]
38. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.
Mackenzie R; Kommoss S; Winterhoff BJ; Kipp BR; Garcia JJ; Voss J; Halling K; Karnezis A; Senz J; Yang W; Prigge ES; Reuschenbach M; Doeberitz MV; Gilks BC; Huntsman DG; Bakkum-Gamez J; McAlpine JN; Anglesio MS
BMC Cancer; 2015 May; 15():415. PubMed ID: 25986173
[TBL] [Abstract][Full Text] [Related]
39. Distinct Histopathologic and Molecular Alterations in Inflammatory Bowel Disease-Associated Intestinal Adenocarcinoma: c-MYC Amplification is Common and Associated with Mucinous/Signet Ring Cell Differentiation.
Hartman DJ; Binion DG; Regueiro MD; Miller C; Herbst C; Pai RK
Inflamm Bowel Dis; 2018 Jul; 24(8):1780-1790. PubMed ID: 29788391
[TBL] [Abstract][Full Text] [Related]
40. Comparison of long-term oncologic outcomes between metastatic ovarian carcinoma originating from gastrointestinal organs and advanced mucinous ovarian carcinoma.
Kajiyama H; Suzuki S; Utsumi F; Yoshikawa N; Nishino K; Ikeda Y; Niimi K; Yamamoto E; Kawai M; Shibata K; Nagasaka T; Kikkawa F
Int J Clin Oncol; 2019 Aug; 24(8):950-956. PubMed ID: 30941534
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
